{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:42:42Z","timestamp":1792975362300,"version":"4.5.0"},"reference-count":83,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) have continued to lag behind outcomes reported for children with acute lymphoblastic leukemia (ALL), in part because of the heterogeneity of the disease, a paucity of targeted therapies, and the relatively slow development of immunotherapy compared with ALL. In addition, we have reached the limits of treatment intensity, and, even with outstanding supportive care, it is highly unlikely that further intensification of conventional chemotherapy alone will impact relapse rates. However, comprehensive genomic analyses and a more thorough characterization of the leukemic stem cell have provided insights that should lead to tailored and more effective therapies in the near future. In addition, new therapies are finally emerging, including the BCL-2 inhibitor venetoclax, CD33- and CD123-directed chimeric antigen receptor T-cell therapy, CD123-directed antibody therapy, and menin inhibitors. Here, we present 4 cases to illustrate some of the controversies regarding the optimal treatment of children with newly diagnosed or relapsed AML.<\/jats:p>","DOI":"10.1182\/blood.2021011694","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T14:52:06Z","timestamp":1623423126000},"page":"1009-1018","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":106,"title":["How I treat pediatric acute myeloid leukemia"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-3527","authenticated-orcid":false,"given":"Jeffrey E.","family":"Rubnitz","sequence":"first","affiliation":[{"name":"Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan J. L.","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center For Pediatric Oncology, Utrecht, The Netherlands; and"},{"name":"Pediatric Oncology, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"issue":"1","key":"2021092315291761600_B1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med."},{"issue":"3","key":"2021092315291761600_B2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell."},{"issue":"4","key":"2021092315291761600_B3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2018.08.014","article-title":"Prospective isolation and characterization of genetically and functionally distinct AML subclones","volume":"34","author":"de Boer","year":"2018","journal-title":"Cancer Cell."},{"issue":"20","key":"2021092315291761600_B4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood.2020007093","article-title":"Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies","volume":"136","author":"Michmerhuizen","year":"2020","journal-title":"Blood."},{"issue":"7834","key":"2021092315291761600_B5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature."},{"issue":"12","key":"2021092315291761600_B6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"issue":"10","key":"2021092315291761600_B7","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia."},{"issue":"27","key":"2021092315291761600_B8","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021092315291761600_B9","doi-asserted-by":"crossref","first-page":"e98561","DOI":"10.1172\/jci.insight.98561","article-title":"Universal monitoring of minimal residual disease in acute myeloid leukemia","volume":"3","author":"Coustan-Smith","year":"2018","journal-title":"JCI Insight."},{"issue":"20","key":"2021092315291761600_B10","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to \u0394N flow cytometry: a Children\u2019s Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv."},{"issue":"13","key":"2021092315291761600_B11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"2021092315291761600_B12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA."},{"issue":"5","key":"2021092315291761600_B13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2021092315291761600_B14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"2021092315291761600_B15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol."},{"issue":"4","key":"2021092315291761600_B16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14737140.2021.1860763","article-title":"Measurable residual disease in pediatric acute myeloid leukemia: a systematic review","volume":"21","author":"Segerink","year":"2021","journal-title":"Exp Rev Anticancer Ther."},{"issue":"27","key":"2021092315291761600_B17","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1200\/JCO.2006.06.5037","article-title":"Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98","volume":"24","author":"Creutzig","year":"2006","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021092315291761600_B18","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"2021092315291761600_B19","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."},{"issue":"5","key":"2021092315291761600_B20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia."},{"issue":"27","key":"2021092315291761600_B21","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021092315291761600_B22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children\u2019s Oncology Group Trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021092315291761600_B23","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group Trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021092315291761600_B24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood."},{"issue":"26","key":"2021092315291761600_B25","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2021092315291761600_B26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021092315291761600_B27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Haematol."},{"issue":"27","key":"2021092315291761600_B28","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021092315291761600_B29","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.19.00327","article-title":"Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial","volume":"37","author":"Rubnitz","year":"2019","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021092315291761600_B30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica."},{"issue":"5","key":"2021092315291761600_B31","doi-asserted-by":"crossref","first-page":"e27605","DOI":"10.1002\/pbc.27605","article-title":"Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01","volume":"66","author":"De Moerloose","year":"2019","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2021092315291761600_B32","doi-asserted-by":"crossref","first-page":"e28692","DOI":"10.1002\/pbc.28692","article-title":"Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: a report from the Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG)","volume":"67","author":"Hasegawa","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"24","key":"2021092315291761600_B33","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2014.59.4473","article-title":"Late mortality after dexrazoxane treatment: a report from the Children\u2019s Oncology Group","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021092315291761600_B34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol."},{"issue":"32","key":"2021092315291761600_B35","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2015.61.5187","article-title":"Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer","volume":"33","author":"Feijen","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021092315291761600_B36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"21","key":"2021092315291761600_B37","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.19.02856","article-title":"Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Getz","year":"2020","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021092315291761600_B38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children\u2019s Oncology Group","volume":"37","author":"Getz","year":"2019","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021092315291761600_B39","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group","volume":"27","author":"Tsukimoto","year":"2009","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021092315291761600_B40","first-page":"1643","article-title":"Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study","volume":"29","author":"Styczynski","year":"2009","journal-title":"Anticancer Res."},{"issue":"36","key":"2021092315291761600_B41","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2015.61.1947","article-title":"Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-M\u00fcnster study group","volume":"33","author":"Klein","year":"2015","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021092315291761600_B42","doi-asserted-by":"crossref","first-page":"e26782","DOI":"10.1002\/pbc.26782","article-title":"Central nervous system disease in pediatric acute myeloid leukemia","volume":"64","author":"Gruber","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2021092315291761600_B43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","article-title":"Current management and challenges of malignant disease in the CNS in paediatric leukaemia","volume":"9","author":"Pui","year":"2008","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021092315291761600_B44","doi-asserted-by":"crossref","first-page":"e26664","DOI":"10.1002\/pbc.26664","article-title":"Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups","volume":"64","author":"Creutzig","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2021092315291761600_B45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia."},{"issue":"12","key":"2021092315291761600_B46","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood."},{"issue":"8","key":"2021092315291761600_B47","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/leu.2011.90","article-title":"The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia","volume":"25","author":"Balgobind","year":"2011","journal-title":"Leukemia."},{"issue":"10","key":"2021092315291761600_B48","doi-asserted-by":"crossref","first-page":"e27266","DOI":"10.1002\/pbc.27266","article-title":"Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations","volume":"65","author":"Yang","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2021092315291761600_B49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bjh.14419","article-title":"Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review","volume":"176","author":"Hasle","year":"2017","journal-title":"Br J Haematol."},{"issue":"10","key":"2021092315291761600_B50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"30","author":"Eidenschink Brodersen","year":"2016","journal-title":"Leukemia."},{"issue":"11","key":"2021092315291761600_B51","doi-asserted-by":"crossref","first-page":"e26632","DOI":"10.1002\/pbc.26632","article-title":"Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada","volume":"64","author":"Alexander","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2021092315291761600_B52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"Hoffman","year":"2021","journal-title":"Expert Rev Anticancer Ther."},{"issue":"5","key":"2021092315291761600_B53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol."},{"issue":"34","key":"2021092315291761600_B54","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021092315291761600_B55","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Cooper","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092315291761600_B56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021092315291761600_B57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"10","key":"2021092315291761600_B58","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"2021092315291761600_B59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021092315291761600_B60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"2021092315291761600_B61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell."},{"issue":"25","key":"2021092315291761600_B62","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2021092315291761600_B63","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol."},{"issue":"6","key":"2021092315291761600_B64","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv."},{"issue":"22","key":"2021092315291761600_B65","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv."},{"issue":"20","key":"2021092315291761600_B66","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"2021092315291761600_B67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica."},{"issue":"17","key":"2021092315291761600_B68","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"2021092315291761600_B69","doi-asserted-by":"crossref","first-page":"e28099","DOI":"10.1002\/pbc.28099","article-title":"Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch Childhood Oncology Group","volume":"67","author":"Klein","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2021092315291761600_B70","doi-asserted-by":"crossref","first-page":"e26254","DOI":"10.1002\/pbc.26254","article-title":"Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: a single-institution report","volume":"64","author":"Rogers","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"7","key":"2021092315291761600_B71","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3109\/10428194.2015.1088652","article-title":"A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"57","author":"Miller","year":"2016","journal-title":"Leuk Lymphoma."},{"issue":"18","key":"2021092315291761600_B72","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2013-01-476614","article-title":"Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children\u2019s Oncology Group","volume":"121","author":"Sung","year":"2013","journal-title":"Blood."},{"issue":"13","key":"2021092315291761600_B73","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.28688","article-title":"Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia","volume":"120","author":"Inaba","year":"2014","journal-title":"Cancer."},{"issue":"2","key":"2021092315291761600_B74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.23563","article-title":"Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia","volume":"113","author":"Kurt","year":"2008","journal-title":"Cancer."},{"issue":"1","key":"2021092315291761600_B75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00277-016-2833-5","article-title":"Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia","volume":"96","author":"Boztug","year":"2017","journal-title":"Ann Hematol."},{"issue":"10","key":"2021092315291761600_B76","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA."},{"issue":"1","key":"2021092315291761600_B77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.15499","article-title":"Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin-Frankf\u00fcrt-M\u00fcnster (I-BFM) study group","volume":"183","author":"Klein","year":"2018","journal-title":"Br J Haematol."},{"issue":"26","key":"2021092315291761600_B78","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2015-07-627323","article-title":"Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia","volume":"126","author":"Halpern","year":"2015","journal-title":"Blood."},{"issue":"3","key":"2021092315291761600_B79","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pbc.24847","article-title":"Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients","volume":"61","author":"Science","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"2021092315291761600_B80","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/PO.20.00257","article-title":"BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies","volume":"4","author":"Lin","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"5","key":"2021092315291761600_B81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/pst.2013","article-title":"Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction","volume":"19","author":"Pan","year":"2020","journal-title":"Pharm Stat."},{"issue":"6","key":"2021092315291761600_B82","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1080\/10543406.2020.1815033","article-title":"Checkerboard: a Bayesian efficacy and toxicity interval design for phase I\/II dose-finding trials","volume":"30","author":"Yin","year":"2020","journal-title":"J Biopharm Stat."},{"issue":"6","key":"2021092315291761600_B83","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pst.2030","article-title":"Bayesian optimal phase II clinical trial design with time-to-event endpoint","volume":"19","author":"Zhou","year":"2020","journal-title":"Pharm Stat."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/12\/1009\/1823643\/bloodbld2021011694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/12\/1009\/1823643\/bloodbld2021011694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T23:52:49Z","timestamp":1632441169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/12\/1009\/476140\/How-I-treat-pediatric-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":83,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6,11]]},"published-print":{"date-parts":[[2021,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011694","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}